AbbVie Inc. (NYSE:ABBV) is Tsfg LLC’s 3rd Largest Position


Share on StockTwits

Tsfg LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 3.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,594 shares of the company’s stock after purchasing an additional 3,189 shares during the period. AbbVie comprises 5.5% of Tsfg LLC’s holdings, making the stock its 3rd largest position. Tsfg LLC’s holdings in AbbVie were worth $10,886,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. BlackRock Inc. boosted its stake in shares of AbbVie by 2.0% in the fourth quarter. BlackRock Inc. now owns 124,423,484 shares of the company’s stock worth $13,331,975,000 after acquiring an additional 2,406,847 shares during the last quarter. Norges Bank purchased a new stake in AbbVie in the fourth quarter valued at $2,070,985,000. Janus Henderson Group PLC raised its holdings in shares of AbbVie by 8.0% in the 4th quarter. Janus Henderson Group PLC now owns 18,332,278 shares of the company’s stock valued at $1,964,269,000 after buying an additional 1,363,299 shares during the period. Morgan Stanley raised its holdings in shares of AbbVie by 19.0% in the 4th quarter. Morgan Stanley now owns 16,336,505 shares of the company’s stock valued at $1,750,457,000 after buying an additional 2,605,050 shares during the period. Finally, UBS Asset Management Americas Inc. raised its holdings in shares of AbbVie by 24.7% in the 4th quarter. UBS Asset Management Americas Inc. now owns 11,438,531 shares of the company’s stock valued at $1,225,639,000 after buying an additional 2,263,374 shares during the period. 67.49% of the stock is currently owned by institutional investors.

Several research firms have recently issued reports on ABBV. Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $114.00 price objective for the company in a research report on Tuesday, February 9th. Morgan Stanley decreased their target price on AbbVie from $120.00 to $116.00 and set an “overweight” rating for the company in a research report on Thursday, January 28th. Mizuho upped their target price on AbbVie from $117.00 to $126.00 and gave the company a “buy” rating in a research report on Thursday, February 4th. They noted that the move was a valuation call. SVB Leerink upped their price objective on AbbVie from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Tuesday, March 30th. Finally, Royal Bank of Canada assumed coverage on AbbVie in a research note on Wednesday, April 7th. They set a $135.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the stock. AbbVie presently has a consensus rating of “Buy” and an average price target of $115.65.

In other news, CEO Richard A. Gonzalez sold 170,113 shares of the business’s stock in a transaction that occurred on Monday, March 1st. The stock was sold at an average price of $108.61, for a total transaction of $18,475,972.93. Following the completion of the transaction, the chief executive officer now directly owns 450,981 shares in the company, valued at $48,981,046.41. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Elaine K. Sorg sold 8,440 shares of the business’s stock in a transaction that occurred on Monday, March 1st. The stock was sold at an average price of $108.61, for a total value of $916,668.40. Following the sale, the senior vice president now directly owns 26,035 shares in the company, valued at approximately $2,827,661.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 198,067 shares of company stock valued at $21,511,667. Insiders own 0.09% of the company’s stock.

Shares of NYSE ABBV opened at $106.89 on Friday. The firm has a market cap of $188.64 billion, a price-to-earnings ratio of 22.60, a PEG ratio of 1.54 and a beta of 0.84. AbbVie Inc. has a 1 year low of $79.11 and a 1 year high of $113.41. The stock’s 50-day simple moving average is $106.82 and its 200-day simple moving average is $101.76. The company has a debt-to-equity ratio of 5.38, a quick ratio of 0.81 and a current ratio of 0.95.

AbbVie (NYSE:ABBV) last issued its earnings results on Tuesday, February 2nd. The company reported $2.92 EPS for the quarter, beating the Zacks’ consensus estimate of $2.85 by $0.07. AbbVie had a return on equity of 439.24% and a net margin of 18.16%. The company had revenue of $13.86 billion during the quarter, compared to the consensus estimate of $13.70 billion. During the same period in the previous year, the firm posted $2.21 earnings per share. AbbVie’s quarterly revenue was up 59.2% compared to the same quarter last year. As a group, research analysts predict that AbbVie Inc. will post 10.48 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 14th. Stockholders of record on Thursday, April 15th will be given a dividend of $1.30 per share. The ex-dividend date is Wednesday, April 14th. This represents a $5.20 annualized dividend and a dividend yield of 4.86%. AbbVie’s dividend payout ratio is presently 58.17%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Further Reading: Calculating net profit and net profit margin ratio

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.